Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera:: Correlation with presence of papillomavirus DNA

被引:18
作者
Rosales, R
López-Contreras, M
Cortes, RR
机构
[1] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Mol Biol, Mexico City 04510, DF, Mexico
[2] Hosp Juarez Mexico, Dept Gynecol, Mexico City, DF, Mexico
关键词
cervical cancer; cryosurgery; cervix; synthetic peptide; Hybrid Capture;
D O I
10.1002/jmv.2098
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human papillomavirus (HPV) infection is associated with cervical cancer. The E2 and E1 papillomavirus proteins are expressed at the early stage of infection and regulate DNA replication. The E2 protein activates and represses transcription from different HPVs promoters. At some stage when viral DNA gets integrated into the cellular genome, the E2 gene is disrupted or inactivated. This event leads to a derepression of the E6 and E7 viral oncogenes. These viral proteins are required normally for the maintenance of the malignant phenotype. Therefore, the E2, E6, and E7 proteins are present in all patients infected by papillomavirus. In this study, the association of antibody levels against E2, E6, and E7 proteins of HPV types 16, 18, and 6 was determined in relation to the presence of HPV DNA at the initial stages of HPV infection. Serum samples from 172 women with HPV infection, determined by Papa-nicolau (Pap) smears and colposcopy, were tested. Elevated antibody titers against E2 protein from the HPV 6 and HPV 16 were detected in 46.42 and 66.96% of the patients, respectively. Antibodies against the E7 and E6 proteins of HPV 16 were found in 51.78 and 36.60% of the patients, respectively. Antibodies against the E6 and E7 proteins of HPV 18 were 35 and 45%, respectively. A statistical difference was found for antibody titers against the E2, E6, and E7 proteins between patients with papillomavirus DNA and controls cases who had no cytological abnormalities and no HPV DNA. Sera titers were 1/500 for patients HPV positive and 1/50 for control individuals. Antibodies titers against E6 and E7 proteins were also examined in patients at 6 and 24 months after cryosurgery. In these patients, a slight decrease in the antibody level against the E2, E6, and E7 proteins was found. No correlation was found between age and number of sexual partners, with serum positivity to the E2, E6, and E7 papillomavirus proteins. These data suggest that antibodies against the E2, E6, and E7 proteins are good candidates for use as markers for monitoring cervical HPV infections. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:736 / 744
页数:9
相关论文
共 53 条
[1]  
[Anonymous], 1974, Introduction to the Theory of Statistics
[2]   Humoral immune response against proteins E6 and E7 in cervical carcinoma patients positive for human papilloma virus type 16 during treatment and follow-up [J].
Baay, MFD ;
Duk, JM ;
Burger, MPM ;
de Bruijn, HWA ;
Stolz, E ;
Herbrink, P .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (02) :126-132
[3]   Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection [J].
Carter, JJ ;
Koutsky, LA ;
Hughes, JP ;
Lee, SK ;
Kuypers, J ;
Kiviat, N ;
Galloway, DA .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1911-1919
[4]   IMMUNOLOGICAL DIAGNOSIS AND MONITORING OF CERVICAL CANCERS USING IN-VITRO TRANSLATED HPV PROTEINS [J].
CHEE, YH ;
NAMKOONG, SE ;
KIM, DH ;
KIM, SJ ;
PARK, JS .
GYNECOLOGIC ONCOLOGY, 1995, 57 (02) :226-231
[5]   A SYNTHETIC PEPTIDE DEFINES A SEROLOGIC IGA RESPONSE TO A HUMAN PAPILLOMAVIRUS-ENCODED NUCLEAR ANTIGEN EXPRESSED IN VIRUS-CARRYING CERVICAL NEOPLASIA [J].
DILLNER, J ;
DILLNER, L ;
ROBB, J ;
WILLEMS, J ;
JONES, I ;
LANCASTER, W ;
SMITH, R ;
LERNER, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) :3838-3841
[6]   DETECTION OF IGA ANTIBODIES AGAINST HUMAN PAPILLOMAVIRUS IN CERVICAL SECRETIONS FROM PATIENTS WITH CERVICAL INTRAEPITHELIAL NEOPLASIA [J].
DILLNER, L ;
BEKASSY, Z ;
JONSSON, N ;
MORENOLOPEZ, J ;
BLOMBERG, J .
INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (01) :36-40
[7]   A PAPILLOMAVIRUS DNA FROM A CERVICAL-CARCINOMA AND ITS PREVALENCE IN CANCER BIOPSY SAMPLES FROM DIFFERENT GEOGRAPHIC REGIONS [J].
DURST, M ;
GISSMANN, L ;
IKENBERG, H ;
ZURHAUSEN, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (12) :3812-3815
[8]   The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer [J].
Fisher, SG ;
BenitezBribiesca, L ;
Nindl, I ;
Stockfleth, E ;
Muller, M ;
Wolf, H ;
PerezGarcia, F ;
GuzmanGaona, J ;
GutierrezDelgado, F ;
Irvin, W ;
Gissmann, L .
GYNECOLOGIC ONCOLOGY, 1996, 61 (01) :73-78
[9]  
GALLOWAY DA, 1990, MOL BIOL MED, V7, P59
[10]   EARLY PROMOTERS OF GENITAL AND CUTANEOUS HUMAN PAPILLOMAVIRUSES ARE DIFFERENTIALLY REGULATED BY THE BOVINE PAPILLOMAVIRUS TYPE-1-E2 GENE-PRODUCT [J].
GUIDO, MC ;
ZAMORANO, R ;
GARRIDOGUERRERO, E ;
GARIGLIO, P ;
GARCIACARRANCA, A .
JOURNAL OF GENERAL VIROLOGY, 1992, 73 :1395-1400